항-IL23 특이적 항체로 크론병을 치료하는 방법

환자에서 크론병을 치료하는 방법은 IL-23 특이적 항체, 예를 들어 구셀쿠맙을 초기 피하 투여량 및 후속 피하 투여량으로 투여하여 환자가 항체에 반응하고 하나 이상의 임상 평가변수(clinical endpoint)를 충족하도록 하는 것이다. A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial subcutaneous dose and subsequent subc...

Full description

Saved in:
Bibliographic Details
Main Authors OLURINDE MOBOLAJI, ADEDOKUN OMONIYI, GERMINARO MATTHEW, YEE JACQUELINE, SAHOO APARNA
Format Patent
LanguageKorean
Published 28.06.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract 환자에서 크론병을 치료하는 방법은 IL-23 특이적 항체, 예를 들어 구셀쿠맙을 초기 피하 투여량 및 후속 피하 투여량으로 투여하여 환자가 항체에 반응하고 하나 이상의 임상 평가변수(clinical endpoint)를 충족하도록 하는 것이다. A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial subcutaneous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
AbstractList 환자에서 크론병을 치료하는 방법은 IL-23 특이적 항체, 예를 들어 구셀쿠맙을 초기 피하 투여량 및 후속 피하 투여량으로 투여하여 환자가 항체에 반응하고 하나 이상의 임상 평가변수(clinical endpoint)를 충족하도록 하는 것이다. A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial subcutaneous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
Author YEE JACQUELINE
GERMINARO MATTHEW
OLURINDE MOBOLAJI
ADEDOKUN OMONIYI
SAHOO APARNA
Author_xml – fullname: OLURINDE MOBOLAJI
– fullname: ADEDOKUN OMONIYI
– fullname: GERMINARO MATTHEW
– fullname: YEE JACQUELINE
– fullname: SAHOO APARNA
BookMark eNrjYmDJy89L5WSwfTt1ra6nj5GxwtuunW_mbnmzoFEBKPRm05bXC-covG1c83rhgtebJ76Z26LwZueM14t73k6d8bprisLrDStfb5rKw8CalphTnMoLpbkZlN1cQ5w9dFML8uNTiwsSk1PzUkvivYOMDIxMDAwsLY1NjRyNiVMFADUdQlE
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID KR20240099352A
GroupedDBID EVB
ID FETCH-epo_espacenet_KR20240099352A3
IEDL.DBID EVB
IngestDate Fri Aug 30 05:43:15 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Korean
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_KR20240099352A3
Notes Application Number: KR20247017433
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240628&DB=EPODOC&CC=KR&NR=20240099352A
ParticipantIDs epo_espacenet_KR20240099352A
PublicationCentury 2000
PublicationDate 20240628
PublicationDateYYYYMMDD 2024-06-28
PublicationDate_xml – month: 06
  year: 2024
  text: 20240628
  day: 28
PublicationDecade 2020
PublicationYear 2024
RelatedCompanies JANSSEN BIOTECH, INC
RelatedCompanies_xml – name: JANSSEN BIOTECH, INC
Score 3.519046
Snippet 환자에서 크론병을 치료하는 방법은 IL-23 특이적 항체, 예를 들어 구셀쿠맙을 초기 피하 투여량 및 후속 피하 투여량으로 투여하여 환자가 항체에 반응하고 하나 이상의 임상 평가변수(clinical endpoint)를 충족하도록 하는 것이다. A method of treating...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title 항-IL23 특이적 항체로 크론병을 치료하는 방법
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240628&DB=EPODOC&locale=&CC=KR&NR=20240099352A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMUoDpowUI3PdpDRLC10TE6Mk3aRkA0vdxGTztNRkYO5LA28K8_Uz8wg18YowjWBiyIHthQGfE1oOPhwRmKOSgfm9BFxeFyAGsVzAayuL9ZMygUL59m4hti5q0N4xqHoyslBzcbJ1DfB38XdWc3a29Q5S8wuCyAFbQ8D2hiMzAyuoIQ06ad81zAm0L6UAuVJxE2RgCwCal1cixMCUnS_MwOkMu3tNmIHDFzrlDWRCc1-xCIPt26lrdT19jIwV3nbtfDN3y5sFjQpAoTebtrxeOEfhbeOa1wsXvN488c3cFoU3O2e8XtzzduqM111TFF5vWPl601RRBmU31xBnD12gO-Lh3o73DkJ2tLEYA0tefl6qBINCCrBZlGRukppqYGEC7I-lWBgnpwA7ucbGhsYpBgaJlpIMMvhMksIvLc3ABeKClkMZWcgwsJQUlabKAivekiQ5cHgBAG2OleU
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMUoDpowUI3PdpDRLC10TE6Mk3aRkA0vdxGTztNRkYO5LA28K8_Uz8wg18YowjWBiyIHthQGfE1oOPhwRmKOSgfm9BFxeFyAGsVzAayuL9ZMygUL59m4hti5q0N4xqHoyslBzcbJ1DfB38XdWc3a29Q5S8wuCyAFbQ8D2hiMzA6s56HxeUOMpzAm0L6UAuVJxE2RgCwCal1cixMCUnS_MwOkMu3tNmIHDFzrlDWRCc1-xCIPt26lrdT19jIwV3nbtfDN3y5sFjQpAoTebtrxeOEfhbeOa1wsXvN488c3cFoU3O2e8XtzzduqM111TFF5vWPl601RRBmU31xBnD12gO-Lh3o73DkJ2tLEYA0tefl6qBINCCrBZlGRukppqYGEC7I-lWBgnpwD9Y2xsaJxiYJBoKckgg88kKfzS8gycHiG-PvE-nn7e0gxcICnQ0igjCxkGlpKi0lRZYCVckiQHDjsAmPiY0g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=%ED%95%AD-IL23+%ED%8A%B9%EC%9D%B4%EC%A0%81+%ED%95%AD%EC%B2%B4%EB%A1%9C+%ED%81%AC%EB%A1%A0%EB%B3%91%EC%9D%84+%EC%B9%98%EB%A3%8C%ED%95%98%EB%8A%94+%EB%B0%A9%EB%B2%95&rft.inventor=OLURINDE+MOBOLAJI&rft.inventor=ADEDOKUN+OMONIYI&rft.inventor=GERMINARO+MATTHEW&rft.inventor=YEE+JACQUELINE&rft.inventor=SAHOO+APARNA&rft.date=2024-06-28&rft.externalDBID=A&rft.externalDocID=KR20240099352A